300832-05-7

Basic information

• Product Name: (E)-(1S,4R,6R,13R,14S,18R)-14-tert-Butoxycarbonylamino-18-(7-methoxy-2-phenyl-quinolin-4-yloxy)-13-methyl-2,15-dioxo-12-oxa-3,16-diaza-tricyclo[14.3.0.0^4,6]nonadec-9-ene-4-carboxylic acid
• Synonyms: (E)-(1S,4R,6R,13R,14S,18R)-14-tert-Butoxycarbonylamino-18-(7-methoxy-2-phenyl-quinolin-4-yloxy)-13-methyl-2,15-dioxo-12-oxa-3,16-diaza-tricyclo[14.3.0.0^4,6]nonadec-9-ene-4-carboxylic acid
• CAS NO: 300832-05-7
• Molecular Weight: 714.816
• Mol File: 300832-05-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (E)-(1S,4R,6R,13R,14S,18R)-14-tert-Butoxycarbonylamino-18-(7-methoxy-2-phenyl-quinolin-4-yloxy)-13-methyl-2,15-dioxo-12-oxa-3,16-diaza-tricyclo[14.3.0.0^4,6]nonadec-9-ene-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-(1S,4R,6R,13R,14S,18R)-14-tert-Butoxycarbonylamino-18-(7-methoxy-2-phenyl-quinolin-4-yloxy)-13-methyl-2,15-dioxo-12-oxa-3,16-diaza-tricyclo[14.3.0.0^4,6]nonadec-9-ene-4-carboxylic acid(300832-05-7)
• EPA Substance Registry System: (E)-(1S,4R,6R,13R,14S,18R)-14-tert-Butoxycarbonylamino-18-(7-methoxy-2-phenyl-quinolin-4-yloxy)-13-methyl-2,15-dioxo-12-oxa-3,16-diaza-tricyclo[14.3.0.0^4,6]nonadec-9-ene-4-carboxylic acid(300832-05-7)

Safety Data

• Hazardous Substances Data: 300832-05-7(Hazardous Substances Data)

Upstream product

• 60538-19-4 N-(tert-butoxycarbonyl)-l-threonine methyl ester 
• 300831-65-6 (1R,2R)-1-{[(2S,4R)-1-((2S,3R)-3-Allyloxy-2-tert-butoxycarbonylamino-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino}-2-but-3-enyl-cyclopropanecarboxylic acid methyl ester 
• 300831-36-1 (2S,3R)-3-Allyloxy-2-tert-butoxycarbonylamino-butyric acid methyl ester 
• 300831-37-2 Boc-Thr(All)-OH 
• 300831-66-7 (E)-(1S,4R,6R,13R,14S,18R)-14-tert-Butoxycarbonylamino-18-(7-methoxy-2-phenyl-quinolin-4-yloxy)-13-methyl-2,15-dioxo-12-oxa-3,16-diaza-tricyclo[14.3.0.0^4,6]nonadec-9-ene-4-carboxylic acid methyl ester 
• 2592-18-9 Boc-Thr-OH 

Relevant articles and documents

Olefin ring-closing metathesis as a powerful tool in drug discovery and development - potent macrocyclic inhibitors of the hepatitis C virus NS3 protease

Peptidomimetic inhibitors of the hepatitis C NS3 protease often exhibit poor biopharmaceutical properties. Structure modification of a substrate-based tripeptide into a β-strand 15-membered ring scaffold provided a new class of peptidomimetics that are si